Screener Summaries Updates Institutions Sign In More Updates › Other Events › CANF Other Events · Jul 6, 2026
Can-Fite BioPharma Ltd. announced on July 6, 2026, that it has completed patient enrollment for the interim analysis… CANF Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. announced on July 6, 2026, that it has completed patient enrollment for the interim analysis of its pivotal Phase 3 psoriasis clinical trial. Data from this analysis is expected to be released in the fourth quarter of 2026 or the first quarter of 2027. The company is a biopharmaceutical firm focused on developing therapeutic products.
More from Can-Fite BioPharma Ltd. EAPO allows patent for Piclidenoson in Lowe syndrome, strengthening IP foundation Nov 2, 2026 Presents final positive Phase IIa data for namodenoson in pancreatic cancer, achieving primary safety endpoint Oct 26, 2026 Can-Fite BioPharma Ltd. reported H1 2026 financial results showing a net loss of $4.6 million, compared to $4.87… Sep 8, 2026 On September 2, 2026, Can-Fite Biopharma Ltd. entered into an inducement offer letter with a warrant holder to… Sep 3, 2026 Can-Fite BioPharma Ltd. announced the exercise of outstanding warrants for approximately $4.0 million in gross… Sep 2, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
